2BBBullish & Bearish
Arbutus Biopharma Corporation (ABUS) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 25 out of 100.
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.
Arbutus Biopharma Corporation’s current 2BB score is 25 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 0 | Very Low |
| Momentum | 50 | Stable |
| Financial strength | 63 | Strong |
| Quality | 40 | Normal |
| Risk | 33 | Low |
| CEO | William H. Collier |
| Headquarters | Warminster Township, Pennsylvania, United States |
| Founded | 2007 |
| Employees | 19 |
| P/E ratio | 5.58 |
| 52-week range | $3.31 – $5.38 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2026-11-11 | — | -0.0204 | — | $1.02M |
| 2026-07-30 | — | -0.0306 | — | $459,000.00 |
| 2026-05-13 | -0.05 | -0.0306 | $385,000.00 | $765,000.00 |
| 2026-03-23 | -0.02 | -0.0357 | $1.05M | $714,000.00 |